Micropep Technologies, a global leader in micropeptide technology, has raised $29 million in a Series B funding round led by Zebra Impact Ventures and BPI Green Tech Investment. Existing investors, including Fall Line Capital, FMC Ventures, Sofinnova Partners, Supernova Invest, and IRDI Capital Investissement, also participated, bringing Micropep’s total funding to over $51.8 million. This new investment will accelerate Micropep’s go-to-market strategy through partnerships, advance regulatory studies of its first biofungicide molecule, and expand its pipeline of micropeptide active ingredients on its newly launched discovery platform, Krisalix.

Investors Support Micropep’s Sustainable Mission

Lionel Artusio, General Partner at Zebra Impact Ventures, emphasized Micropep’s potential to revolutionize sustainable agriculture. “Micropep’s pioneering micropeptide technology holds immense promise for revolutionizing agriculture sustainably,” said Artusio. Baptiste Tellier, Managing Director of Fall Line Capital, highlighted Micropep’s strides in maintaining field efficacy of micropeptides while reducing doses and biomanufacturing costs, along with integrating AI tools into its discovery platform to shorten design turnaround times.

Introducing Krisalix: Micropep’s Proprietary Discovery Platform

Micropep’s Krisalix platform combines proprietary micropeptide design algorithms with a unique suite of bioassays to accelerate the discovery of new micropeptide-based active ingredients for crop protection. This platform enables rapid identification of the most promising micropeptide molecules by assessing their efficacy, stability, and production feasibility.

Thomas Laurent, CEO and co-founder of Micropep, noted, “This new round of funding, happening in a particularly complex financing environment, is a great mark of recognition of both the exceptional results we achieved so far at Micropep and the future potential of our micropeptide discovery platform and first active ingredients.”

Strategic Partnerships and Future Growth

Micropep aims to establish strategic partnerships across the R&D, manufacturing, commercial, and distribution stages of product development. “Micropeptides have a unique value proposition, combining new modes of actions, strong efficacy in the field, great safety profile, and affordable costs for farmers,” Laurent explained. The company plans to enhance its research efforts in France to further develop Krisalix and improve its testing capabilities.

Micropep’s vision is to scale its innovative, sustainable solutions for crop protection and make them accessible to farmers worldwide, contributing to the global challenge of sustainable food production. Laurent concluded, “Our investors have shown confidence in our approach, and we will reward them with an ongoing commitment to creating innovative, sustainable AgTech solutions for a better world.”